A compound of Formula (I) their polymorphs, stereoisomers, solvates, co-crystals, and pharmaceutically acceptable salts thereof, wherein, X is O or S; Y is selected from O or N; Z is N; A is CR 1 ; B is CR 2 ; n is 0 or 1; R 1 and R 2 are hydrogen; R 3 is absent or is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C(O)C 1-6 alkyl, SO 2 C 3-6 cycloalkyl, SO 2 C 6 aryl, and SO 2 C 1-6 alkyl, wherein, SO 2 C 1-6 alkyl, and SO 2 C 6 aryl is optionally substituted with a substituent selected from C 1-6 alkoxy, halogen, and C 6 aryl; R 10 and R 11 are taken together to form a 5-6 membered monocyclic saturated heterocyclic ring, wherein, the 5-6 membered monocyclic saturated heterocyclic ring is optionally substituted with the substituents selected from amino, -NHC(O)CH=CHCH 2 N(CH 3 ) 2 , or C 1-6 alkylamino; R 12 , R 13 , R 14 and R 15 are independently selected from hydrogen or C 1-6 alkyl; and R 16 is selected from 5-10 membered bicyclic heteroaryl with 1-2 heteroatoms selected from N or S, wherein, 5-10 membered bicyclic heteroaryl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C 6 aryl, C 2-6 alkenyl-C 6 aryl, C 1-6 alkyl-C 1-6 heterocyclyl, C 1-6 heteroaryl, and C 1-6 alkyl-C 1-6 heteroaryl, wherein, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C 6 aryl, C 1-6 heteroaryl, C 1-6 alkyl-C 1-6 heteroaryl, and C 1-6 alkyl-C 1-6 heterocyclyl is optionally substituted with one or more of the groups selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, C 1-6 heteroaryl, halogen, hydroxyl, -CH 2 OH, and -COOH. their polymorphs, stereoisomers, solvates, co-crystals, and pharmaceutically acceptable salts thereof, wherein, X is O or S; Y is selected from O or N; Z is N; A is CR 1 ; B is CR 2 ; n is 0 or 1; R 1 and R 2 are hydrogen; R 3 is absent or is selected from hydrogen, C 1-6 alkyl, C 3-6 cycloalkyl, C(O)C 1-6 alkyl, SO 2 C 3-6 cycloalkyl, SO 2 C 6 aryl, and SO 2 C 1-6 alkyl, wherein, SO 2 C 1-6 alkyl, and SO 2 C 6 aryl is optionally substituted with a substituent selected from C 1-6 alkoxy, halogen, and C 6 aryl; R 10 and R 11 are taken together to form a 5-6 membered monocyclic saturated heterocyclic ring, wherein, the 5-6 membered monocyclic saturated heterocyclic ring is optionally substituted with the substituents selected from amino, -NHC(O)CH=CHCH 2 N(CH 3 ) 2 , or C 1-6 alkylamino; R 12 , R 13 , R 14 and R 15 are independently selected from hydrogen or C 1-6 alkyl; and R 16 is selected from 5-10 membered bicyclic heteroaryl with 1-2 heteroatoms selected from N or S, wherein, 5-10 membered bicyclic heteroaryl is optionally substituted with 1-3 substituents selected from the group consisting of halogen, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C 6 aryl, C 2-6 alkenyl-C 6 aryl, C 1-6 alkyl-C 1-6 heterocyclyl, C 1-6 heteroaryl, and C 1-6 alkyl-C 1-6 heteroaryl, wherein, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkyl-C 6 aryl, C 1-6 heteroaryl, C 1-6 alkyl-C 1-6 heteroaryl, and C 1-6 alkyl-C 1-6 heterocyclyl is optionally substituted with one or more of the groups selected from hydrogen, C 1-6 alkyl, C 1-6 alkoxy, C 3-8 cycloalkyl, C 1-6 heteroaryl, halogen, hydroxyl, -CH 2 OH, and -COOH. <EOS>